Protein Kinase C-Associated Kinase PKK is Required for NF-kB Signaling and Survival in Diffuse Large-B Cell Lymphoma Cells

This invention provides a novel drug target for the treatment of B-cell lymphoma.  NFkB plays an important role in the proliferation and the survival of many types of B lymphoma cells.  Inhibition of the novel target will lead to inactivation of transcript factor NFkB in specific cell targets and cause certain types of B lymphoma cells death, providing a potential therapy for certain B lymphoma patients.

CHOP plus Rituximab (antiCD20) chemotherapy is currently used for the treatment of Diffuse Large B cell Lymphoma.  Rituxinab treatment can only be effective for the cells the express CD20 on the cell surface.  CD20 negative cells, such as stem cells, will be resistant to the Rituxinab treatment. In addition, clinically about half of lymphoma patients are resistant to CHOP treatment.  Since down-regulating this novel target will sensitize the cells to CHOP and other chemotherapeutic agents, this novel therapeutic approach could be developed to enhance greatly the efficacy of current chemotherapeutic treatments.

URV Reference Number: 6-1616
Patent Information:
Title Country Patent No. Issued Date
Methods of Treating B-Cell Cancers United States 8,367,633 2/5/2013
For Information, Contact:
Weimin Kaufman
Licensing Manager
University of Rochester
Luojing Chen
Jiyong Zhao
Cell Signalling